Prostamax (20 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily intramuscularly. Preclinical studies used daily IM administration for 15 to 60 days. For volumes under 10 units, 30- or 50-unit insulin syringes improve precision.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light; use within 2 weeks. At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg (0.1 mg) on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized (short-term): refrigerate at 4 °C in dry, dark conditions.
• Lyophilized (long-term): store at -20 °C for extended stability.
• Reconstituted: refrigerate at 2 to 8 °C; use within ~2 weeks; avoid freeze-thaw.

Supplies Needed

Plan based on an 8 to 16 week daily protocol.

Peptide Vials (Prostamax, 20 mg each):

• 8 weeks: ~2 vials (~40 mg total at 0.7 mg/day average).
• 12 weeks: ~3 vials (~60 mg total).
• 16 weeks: ~4 vials (~80 mg total at 1 mg/day maintenance).

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 weeks (2 vials): 1 bottle. 12 weeks (3 vials): 1 bottle. 16 weeks (4 vials): 1 bottle.

Alcohol Swabs:

• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile syringes or appropriate IM syringes; dispose in a sharps container.
• Rotate injection sites among large muscle groups (deltoid, vastus lateralis, gluteus).
• Inject slowly; wait a few seconds before withdrawing the needle.
• For volumes under 10 units, use 30- or 50-unit syringes for better precision.

How This Works

Prostamax (KEDP) belongs to the class of short bioregulatory peptides studied by Khavinson and colleagues. These tetrapeptides are proposed to modulate gene expression through epigenetic mechanisms, interacting with chromatin structure and histone proteins. In aged human lymphocytes, KEDP has been observed to cause pericentromeric chromatin decondensation, potentially reactivating suppressed genes. Preclinical rat models of prostatitis showed that IM administration of KEDP reduced inflammatory markers and helped prevent fibrotic changes in prostate tissue.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• In rat prostatitis models, IM KEDP administration reduced inflammation and supported tissue

normalization over 15 to 60 days.

• Studies in benign prostatic hyperplasia models showed favorable effects on prostate weight and

histological parameters.

• Short bioregulatory peptides of this class generally show favorable tolerability profiles in preclinical work.
• Potential for mild injection-site reactions (redness, tenderness) as with any IM administration; rotate sites

to minimize.

• Human clinical trial data are not yet published; dosing is extrapolated from animal models.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a balanced diet rich in vegetables, healthy fats, and adequate protein.
• Regular physical activity supports circulation and overall metabolic health.
• Adequate hydration and limiting alcohol or caffeine may support urinary function.
• Prioritize sleep and stress management to support immune and hormonal balance.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry completely.
2. For IM injection, use a 22 to 25 gauge, 1 to 1.5 inch needle inserted at 90 degrees into a large muscle (deltoid, vastus lateralis, or gluteus).
3. Aspiration before IM injection is no longer routinely recommended for most sites.
4. Inject slowly and steadily; wait briefly before withdrawing.
5. Rotate sites systematically to avoid muscle irritation or fibrosis.

References

Source citations for further reading.

1. Experimental study of Prostamax efficiency in chronic aseptic prostatitis therapy (Modern Research in Inflammation, 2013).
2. Effects of short peptides on lymphocyte chromatin in senile subjects (Bulletin of Experimental Biology and Medicine, 2004).